**Contact:** Stanley Wunderlich, CEO

Consulting for Strategic Growth 1, LTD

Tel: 1-800-625-2236

Fax: 1-646-205-7771

Email: swunderlich@cfsg1.com

****

***BioCorRx®***

***CFSG1 CASE STUDY UPDATE: March 2017***

***LOS ANGELES, CA -- (Marketwired) -- 11/18/15 -- BioCorRx, Inc. (OTCQB: BICX), developer of the BioCorRx® Recovery Program, a Medication-Assisted Treatment (MAT) program, announced today they have entered into an agreement to engage the global business and capital markets advisory firm, Tactical Growth Partners "TGP". The principals of TGP have over seventy-five years of Wall Street experience within the small-cap, emerging growth global market as well as in the fields of medicine, medical technology and business development. TGP will provide assistance with strategic planning and business development, general advisory services, communications to the financial community and other services as agreed to.***

***"We are pleased to announce our new relationship with TGP. As we continue to grow and evolve, we look forward to leaning on the expertise of the experienced the professionals at TGP. Many of their past clients have up-listed to national exchanges, and BioCorRx sees a benefit in positioning ourselves to up-list to a higher exchange at some point in the future," stated BioCorRx, Inc. COO and interim CEO, Brady Granier.***

***Stanley Wunderlich, a Principal of TGP stated, "We look forward to working with BioCorRx, Inc. TGP's experience, skill sets and a strong database of contacts combined with the Company's distribution model for rapid growth and increased brand awareness are very synergistic. TGP along with its wholly owned subsidiary, Launchpad IR, has worked with many public and private companies over the years and look forward to helping build another success story."***

***The Company wanted to increase their public market valuation and increase their daily trading volume, and help raise additional capital.***

***SANTA ANA, CA -- (Marketwired) -- 06/20/16 -- Alpine Creek Capital Partners ("Alpine Creek") and BioCorRx, Inc. (OTC PINK: BICX) ("BioCorRx" or "the Company") are pleased to announce an investment by Alpine Creek in the Company. The Company specializes in solutions for alcohol and opioid addiction treatment using its proprietary, non-addictive medication-assisted treatment (MAT) program called the BioCorRx® Recovery Program. The Company has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of an FDA-approved medicine, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant can significantly reduce cravings for alcohol or opioids for several months, depending on individual metabolism rates. In addition to the implant formulation, and perhaps more important, is the Company's comprehensive counseling program that was developed by addiction experts specific to individuals undergoing treatment with any form of sustained-release naltrexone.***

***Travis Mullen, Managing Partner of Alpine Creek Capital Partners, said, "We couldn't be more excited about our investment in BioCorRx and the cutting edge program they have in place. The BioCorRx® Recovery Program which includes this naltrexone delivery system coupled with the tangible counseling program is literally saving lives and we look forward to arming as many families as possible with this amazing tool for their battle against alcohol or opioid addiction."***

***The initial investment in the Company is $2,500,000 with an additional $2,500,000 expected within six months at the option of Alpine Creek. Details of the transaction can be found in the Company's filings with the Securities and Exchange Commission. In the coming weeks and months, the Company will announce its plans and initiatives for using the capital received from Alpine Creek***

***More to follow during 2017***

***Consulting for Strategic Growth 1, Ltd. (hereinafter referred to as “CFSG1”) prepares and/or publishes various publications, including press releases and corporate profiles, on behalf of private and public companies. CFSG1 also publishes its own publications, including “CEO Interviews” and “The Small Cap Review”. These publications contain information about the companies and/or their securities. In accordance with agreements that CFSG1 has with its clients, it distributes these publications via Email, the U.S. mails, or facsimile.***

***No information contained in CFSG1’s publications should be considered as a solicitation to purchase or sell a company’s securities. CFSG1 is not a registered investment advisor or a registered securities broker dealer. CFSG1 does not undertake or represent to make investment recommendations or provide advice pertaining to the purchase or sale of securities mentioned in its publications. The information contained in CFSG1’s publications is compiled by CFSG1 based upon sources that it believes to be reliable; however, CFSG1 does not guarantee the accuracy of any information contained in the publications. CFSG1 does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data pertaining to its client companies. Investors should not rely solely on the information contained in CFSG1’s or a client company’s publications when making an investment decision. Instead, investors should use the information provided only as a starting point for conducting additional research that will permit them to form their own opinions regarding the companies. The receipt of the information contained in CFSG1’s publications shall not create, under any circumstance, any implication that there has been no change in the affairs of a client company since the date of the publication regarding the client company.***

***Statements made in any of CFSG1’s or a client company’s publications that are not historical facts are “forward looking statements” that involve risks and uncertainties. These statements may be identified by the use of terminology such as “believes”, “expects,”, “may”, “will”, “should”, or “anticipates”. The actual results of a company’s operations, financial condition, or other aspects of its business could differ materially from those discussed in the publications. The information contained in CFSG1’s publications may pertain to small cap and/or thinly traded securities, which by their nature involve an extremely high degree of risk. Investment in such securities could result in the loss of some or all of an investment. In addition, due to the illiquid nature of some of these securities, an investor may be unable to sell his or her securities.***

***CFSG was paid both in cash and restricted stock for its investor relations/strategic services to the Company.***